Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

British Journal of Haematology

Volumn 142, Issue 3, 2008, Pages 379-393

  Gabrilove, Janice ^a   Paquette, Ronald ^b   Lyons, Roger M ^c   Mushtaq, Chaudhry ^d   Sekeres, Mikkael A ^e   Tomita, Dianne ^f   Dreiling, Lyndah ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d South Carolina Oncology Associates   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f AMGEN INC   (United States)

Author keywords

Erythroid response; Erythropoiesis stimulating agent; Haemoglobin; Myelodysplastic syndromes; Transfusion

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ADULT; AGED; ANEMIA; AORTA STENOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEOPLASM; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RESPIRATORY ARREST; RETINA ARTERY OCCLUSION; SEIZURE; SEPSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TIME FACTORS; TREATMENT OUTCOME;

EID: 46949086842     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07181.x     Document Type: Article

References (50)

1. Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. Tura, S. (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 1286 1306.
2. Allampallam, K., Shetty, V., Mundle, S., Dutt, D., Kravitz, H., Reddy, P.L., Alvi, S., Galili, N., Saberwal, G.S., Anthwal, S., Shaikh, M.W., York, A. Raza, A. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. International Journal of Hematology, 75, 289 297.
3. Balducci, L. (2006) Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer, 106, 2087 2094.
4. Balleari, E., Rossi, E., Clavio, M., Congiu, A., Gobbi, M., Grosso, M., Secondo, V., Spriano, M., Timitilli, S. Ghio, R. (2006) Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Annals of Hematology, 85, 174 180.
5. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189 199.
6. Bokemeyer, C., Aapro, M.S., Courdi, A., Foubert, J., Link, H., Osterborg, A., Repetto, L. Soubeyran, P. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer, 40, 2201 2216.
7. Bowen, D.T. Hellstrom-Lindberg, E. (2001) Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? Leukemia Research, 25, 19 21.
8. Brooks, R., Rabin, R. de Charro, F. (eds 2003) The Measurement and Validation of Health Status Using EQ-5D: A European Perspective. Evidence from the EuroQol BIOMED Research Programme. Kluwer Academic Publishers, Rotterdam.
9. Canon, J.L., Vansteenkiste, J., Bodoky, G., Mateos, M.V., Bastit, L., Ferreira, I., Rossi, G. Amado, R.G. (2006) Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Journal of the National Cancer Institute, 98, 273 284.
10. Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarre, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. Fenaux, P. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 104, 321 327.
11. Catenacci, D.V. Schiller, G.J. (2005) Myelodysplasic syndromes: a comprehensive review. Blood Reviews, 19, 301 319.
12. Cella, D., Eton, D.T., Lai, J.S., Peterman, A.H. Merkel, D.E. (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547 561.
13. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671 3674.
14. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A., Kantarjian, H., Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419 425.
15. Faderl, S. Kantarjian, H.M. (2004) Novel therapies for myelodysplastic syndromes. Cancer, 101, 226 241.
16. Gardin, C. Fenaux, P. (2004) Supportive care including growth factors in myelodysplastic syndromes. Reviews in Clinical and Experimental Hematology, 8, E3.
17. Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R.E., Boccia, R.V., Tomita, D. Rossi, G. (2006) Randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24, 2290 2297.
18. Golshayan, A.R., Jin, T., Maciejewski, J., Fu, A.Z., Bershadsky, B., Kattan, M.W., Kalaycio, M.E., Sekeres, M.A., Golshayan, A.-R., Jin, T., Maciejewski, J., Fu, A.Z., Bershadsky, B., Kattan, M.W., Kalaycio, M.E. Sekeres, M.A. (2007) Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. British Journal of Haematology, 137, 125 132.
19. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. (see comment) (erratum appears in Blood 1998 Feb 1;91(3):1100). Blood, 89, 2079 2088.
20. Greenberg, P.L., Baer, M.R., Bennett, J.M., Bloomfield, C.D., DeCastro, C.M., Deeg, H.J., Devetten, M., Emanuel, P.D., Erba, H.P., Estey, E., Foran, J., Gore, S.D., Millenson, M., Navarro, W., Nimer, S.D., O'Donnell, M.R., Saba, H.I., Spiers, K., Stone, R.M. Tallman, M.S. (2006) Clinical practice guidelines in oncology: myelodysplastic syndromes. v.4.2006 ed: National Comprehensive Cancer Network. http://www.nccn.org. Accessed August 23, 2006.
21. Gupta, P., LeRoy, S.C., Luikart, S.D., Bateman, A. Morrison, V.A. (1999) Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leukemia Research, 23, 953 959.
22. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394 403.
23. Hellstrom-Lindberg, E. (2005) Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program), 161 166.
24. Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 68 75.
25. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 1037 1046.
26. Herrington, J.D., Davidson, S.L., Tomita, D.K., Green, L., Smith, R.E. Boccia, R.V. (2005) Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. American Journal of Health-System Pharmacy, 62, 54 62.
27. Hofmann, W.K. Koeffler, H.P. (2005) Myelodysplastic syndrome. Annual Review of Medicine, 56, 1 16.
28. Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A., Hellstrom-Lindberg, E., Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803 811.
29. Jadersten, M., Malcovati, L., Dybedal, I., Della Porta, M., Invernizzi, R., Montgomery, S.M., Pascutto, C., Portwit-MacDonald, A., Cazzola, M. Hellstrom-Lindberg, E. (2006) Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood, 108, 521 (Abstract).
30. Jelkmann, W.E., Fandrey, J., Frede, S. Pagel, H. (1994) Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Annals of the New York Academy of Sciences, 718, 300 309.
31. Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., Rossi, G. Mackey, J. (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39, 2026 2034.
32. Kurtin, S.E. (2006) Advances in the management of low- to intermediate-risk myelodysplastic syndrome: integrating the National Comprehensive Cancer Network guidelines. Clinical Journal of Oncology Nursing, 10, 197 208.
33. Mannone, L., Gardin, C., Quarre, M.C., Bernard, J.F., Vassilieff, D., Ades, L., Park, S., Vaultier, S., Hamza, F., Beyne-rauzy, M.O., Cheze, S., Giraudier, S., Agape, P., Legros, L., Voillat, L., Dreyfus, F. Fenaux, P. (2006) High-dose darbepoetin alfa in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology, 133, 513 519.
34. Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A., Sanpaolo, G., Bodenizza, C., Scalzulli, P.R., La Sala, A., Campioni, D., Ghio, R., Cascavilla, N. Carella, A.M. (2005) Darbepoetin alfa for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology, 128, 204 209.
35. Patton, J.F., Sullivan, T., Mun, Y., Reeves, T., Rossi, G. Wallace, J.F. (2005) A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. The Journal of Supportive Oncology, 3, 419 426.
36. Raza, A., Mundle, S., Shetty, V., Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H. Gregory, S. (1996) Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. International Journal of Hematology, 63, 265 278.
37. Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C.L., Cella, D., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Lee, S.J., Miller, C.B., Rarick, M.U., Regan, D.H., Browman, G.P. Gordon, M.S. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 2303 2320.
38. Robinson, D.M. Easthope, S.E. (2005) Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs, 19, 327 343.
39. Rodgers, G.M., Cella, D., Chanan-Khan, A., Chesney, C., Cleeland, C., Coccia, P.F., Demetri, G.D., Djulbegovic, B., Garst, J.L., Gore, M., Kraut, E.H., Lin, W.-C., Millenson, M., Mock, V., Reinke, D., Rosenthal, J. Sabbatini, P. (2005) Cancer- and treatment-related anemia: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 3, 772 789.
40. Rose, E.H., Abels, R.I., Nelson, R.A., McCullough, D.M. Lessin, L. (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). British Journal of Haematology, 89, 831 837.
41. Schwartzberg, L.S., Yee, L.K., Senecal, F.M., Charu, V., Tomita, D., Wallace, J. Rossi, G. (2004) A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist, 9, 696 707.
42. Sekeres, M.A. List, A. (2006) Immunomodulation in myelodysplastic syndromes. Best Practice & Research. Clinical Haematology, 19, 757 767.
43. Sekeres, M.A., Fu, A.Z., Maciejewski, J.P., Golshayan, A.R., Kalaycio, M.E. Kattan, M.W. (2007) A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer, 109, 1125 1132.
44. Spiriti, M.A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., Volpe, E., Clavio, M., Grossi, A., Reyes, M.T., Musto, P., Mitra, M.E., Azzara, A., Pagnini, D., D'Arena, G., Spadano, A., Balleari, E., Pecorari, P., Capochiani, E., De Biasi, E., Perego, D., Monarca, B., Pisani, F., Scaramella, G. Petti, M.C. (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology, 84, 167 176.
45. Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E. Amadori, S. (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Annals of Oncology, 16, 1921 1927.
46. Stifter, G., Heiss, S., Gastl, G., Tzankov, A. Stauder, R. (2005) Over-expression of tumor necrosis factor-alfa in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. European Journal of Haematology, 75, 485 491.
47. Tehranchi, R. (2006) Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Medical Oncology, 23, 37 49.
48. Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B. Musil, J. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 1211 1220.
49. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 2302.
50. Verma, A. List, A.F. (2005) Cytokine targets in the treatment of myelodysplastic syndromes. Current Hematology Reports, 4, 429 435.